Denali Therapeutics Inc (FRA:4DN)
€ 20.31 -0.18 (-0.88%) Market Cap: 2.85 Bil Enterprise Value: 2.09 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 54/100

Denali Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 06:30PM GMT
Release Date Price: €18.46 (+5.25%)
Jessica Fye J.P. Morgan Securities LLC;Moderator

Great. Good morning, everyone. My name is Jess Fye. I'm a senior biotech analyst at J.P. Morgan, and we're continuing the conference this morning with Denali.

I'm joined on stage by the company's CEO, Ryan Watts. (Conference Instructions)

So with that, let me pass it over to Ryan.

Ryan Watts Denali Therapeutics Inc;CEO

Great. Thank you, Jess. Great to be back at JPMorgan. Great to see many of you friends and colleagues over the years and very excited to present our update for 2024 and talk a little bit about what's happened in the last year and set the stage for the company going forward.

So let me begin by saying that as we founded Denali, our primary purpose that we set out to after was to defeat degeneration and to focus on some of the broader degenerative diseases like Alzheimer's and Parkinson's. But you'll recall, eight or nine years ago, it's a very difficult time in the space, and yet so much has changed in the last two to three years, especially in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot